Supplementary Table 1 for Special editorial: When prescribing Janus kinase inhibitors for dermatologic conditions, be mindful of the Food and Drug Administration’s September 1,2021, data safety communication

Supplementary Table 1 for Special editorial: When prescribing Janus kinase inhibitors for dermatologic conditions, be mindful of the Food and Drug Administration’s September 1,2021, data safety communication.《皮肤病适应证处方贾努斯激酶抑制剂（Janus kinase inhibitors）时需留意美国食品药品监督管理局（Food and Drug Administration）2021年9月1日发布的数据安全公告》特约社论的补充表1